{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37","upperLimit":"43","value":"43"},{"groupId":"OG001","lowerLimit":"29","upperLimit":"41","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Time to Hb response is defined as the number of study days until the first occurrence of an Hb response. Participants without events were censored at the time of evaluation. Median and 95 percent (%) confidence interval (CI) were estimated using Kaplan-Meier Survival Analysis. Hb response was an observed increase in Hb \\>=1.0 g/dL from baseline and an Hb concentration \\>= 10.0 g/dL before the end of the study without RBC transfusion before response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.","id":"OG000","title":"Mircera"},{"description":"Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.","id":"OG001","title":"Darbepoetin Alfa"}],"paramType":"MEDIAN","populationDescription":"ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 28","title":"Time to Hemoglobin Response","type":"SECONDARY","unitOfMeasure":"days"}